Harmony Biosciences/$HRMY
1D1W1MYTD1Y5YMAX
Capital at risk
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
- Ticker
- $HRMY
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 293
- Headquarters
- Plymouth Meeting, United States
- Website
- www.harmonybiosciences.com
HRMY Metrics
BasicAdvanced
$2.5B
13.61
$3.09
0.91
-
Price and volume
Market cap
$2.5B
Beta
0.91
52-week high
$43.49
52-week low
$25.52
Average daily volume
774K
Financial strength
Current ratio
3.479
Quick ratio
3.327
Long term debt to equity
13.884
Total debt to equity
16.031
Interest coverage (TTM)
17.12%
Profitability
EBITDA (TTM)
255.987
Gross margin (TTM)
75.42%
Net profit margin (TTM)
18.88%
Operating margin (TTM)
24.03%
Effective tax rate (TTM)
24.85%
Revenue per employee (TTM)
$3,280,000
Management effectiveness
Return on assets (TTM)
11.62%
Return on equity (TTM)
20.46%
Valuation
Price to earnings (TTM)
13.61
Price to revenue (TTM)
2.53
Price to book
2.45
Price to tangible book (TTM)
2.65
Price to free cash flow (TTM)
7.999
Free cash flow yield (TTM)
12.50%
Free cash flow per share (TTM)
5.259
Growth
Revenue change (TTM)
24.25%
Earnings per share change (TTM)
-0.15%
3-year revenue growth (CAGR)
24.38%
3-year earnings per share growth (CAGR)
-1.92%
What the Analysts think about HRMY
Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.
Analyst projections of the future price of Harmony Biosciences stock.
Bulls say / Bears say
Q2 2026 WAKIX net product revenue surged 30% YoY to $261.3 million, marking a new quarterly record and underscoring blockbuster momentum for its pitolisant franchise (SEC Filing)
Harmony has secured settlements with six of seven ANDA filers, ensuring WAKIX exclusivity into March 2030 and positioning the franchise for extensions into the 2040s via next-generation formulations (Harmony Biosciences PR)
Multiple near-term pipeline catalysts—mid-2026 Phase 1 PK data for BP-205, a Q2 2026 NDA submission for Pitolisant GR, and ongoing Phase 3 trials for pitolisant HD and Prader-Willi syndrome—support potential upside beyond WAKIX (Business Wire)
Q2 2026 cost of goods sold jumped 66% year-over-year to $63.2 million, lifting the COGS margin to 24.2% from 19.0% and compressing gross margins due to new royalties under the Novitium license agreement (Harmony Biosciences PR)
With over 99% of revenues generated by a single product (WAKIX), Harmony remains highly exposed to generic competition post-2030, a concentration risk reflected in its discounted forward P/E multiple (Zacks)
R&D expenses more than doubled to $69.4 million in Q1 2026 (101% YoY), driven by upfront licensing payments that weighed on profitability and led to a net income decline despite revenue growth (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2026.
HRMY Financial Performance
Revenues and expenses
HRMY Earnings Performance
Company profitability
Upcoming events
No upcoming events
HRMY News
AllArticlesVideos
Funds containing HRMY
AllUSDEURGBP
Fund name | Fund size | $HRMY weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.21% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.21% |
iShares Healthcare Innovation£DRDR | £1B | 0.21% |
iShares Ageing Population€AGED | €822M | 0.16% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.